Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gene Colice

Showing results (41-50 of 65) with videos related to

Pageof 7
Sort By:
The European Respiratory Journal|June 11, 2021
Patient characteristics, biomarkers and exacerbation risk in severe, uncontrolled asthmaMonica Kraft, Guy Brusselle, J Mark FitzGerald, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 13, 2016
ReplyWillem M C van Aalderen, Jonathan Grigg, Theresa W Guilbert, et al.
Respiratory Research|October 14, 2020
SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthmaMichael E Wechsler, Gene Colice, Janet M Griffiths, et al.
Respiratory Research|October 14, 2020
NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthmaAndrew Menzies-Gow, Gene Colice, Janet M Griffiths, et al.
Pragmatic and Observational Research|August 22, 2018
Performance of database-derived severe exacerbations and asthma control measures in asthma: responsiveness and predictive utility in a UK primary care database with linked questionnaire dataGene Colice, Alison Chisholm, Alexandra L Dima, et al.
The Journal of Allergy and Clinical Immunology|May 10, 2022
Feno differentiates epithelial gene expression clusters: Exploratory analysis from the MESOS randomized controlled trialSarah Diver, Sriram Sridhar, Latifa C Khalfaoui, et al.
The Journal of Allergy and Clinical Immunology|August 10, 2010
Prescribing practices and asthma control with hydrofluoroalkane-beclomethasone and fluticasone: a real-world observational studyDavid Price, Richard J Martin, Neil Barnes, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|June 1, 2023
Effect of tezepelumab on healthcare utilization in patients with severe, uncontrolled asthma: The NAVIGATOR studyAndrew Menzies-Gow, Arnaud Bourdin, Geoffrey Chupp, et al.
The Lancet. Respiratory Medicine|July 13, 2021
Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trialSarah Diver, Latifa Khalfaoui, Claire Emson, et al.
International Journal of Chronic Obstructive Pulmonary Disease|November 8, 2014
Comparing the effectiveness of small-particle versus large-particle inhaled corticosteroid in COPDDirkje S Postma, Nicolas Roche, Gene Colice, et al.
Pageof 7

Showing results (41-50 of 65) with videos related to

Sort By:
Pageof 7
The European Respiratory Journal|June 11, 2021
Patient characteristics, biomarkers and exacerbation risk in severe, uncontrolled asthmaMonica Kraft, Guy Brusselle, J Mark FitzGerald, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 13, 2016
ReplyWillem M C van Aalderen, Jonathan Grigg, Theresa W Guilbert, et al.
Respiratory Research|October 14, 2020
SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthmaMichael E Wechsler, Gene Colice, Janet M Griffiths, et al.
Respiratory Research|October 14, 2020
NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthmaAndrew Menzies-Gow, Gene Colice, Janet M Griffiths, et al.
Pragmatic and Observational Research|August 22, 2018
Performance of database-derived severe exacerbations and asthma control measures in asthma: responsiveness and predictive utility in a UK primary care database with linked questionnaire dataGene Colice, Alison Chisholm, Alexandra L Dima, et al.
The Journal of Allergy and Clinical Immunology|May 10, 2022
Feno differentiates epithelial gene expression clusters: Exploratory analysis from the MESOS randomized controlled trialSarah Diver, Sriram Sridhar, Latifa C Khalfaoui, et al.
The Journal of Allergy and Clinical Immunology|August 10, 2010
Prescribing practices and asthma control with hydrofluoroalkane-beclomethasone and fluticasone: a real-world observational studyDavid Price, Richard J Martin, Neil Barnes, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|June 1, 2023
Effect of tezepelumab on healthcare utilization in patients with severe, uncontrolled asthma: The NAVIGATOR studyAndrew Menzies-Gow, Arnaud Bourdin, Geoffrey Chupp, et al.
The Lancet. Respiratory Medicine|July 13, 2021
Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trialSarah Diver, Latifa Khalfaoui, Claire Emson, et al.
International Journal of Chronic Obstructive Pulmonary Disease|November 8, 2014
Comparing the effectiveness of small-particle versus large-particle inhaled corticosteroid in COPDDirkje S Postma, Nicolas Roche, Gene Colice, et al.
Pageof 7